Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.22B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.28M
Average 0.31M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Pharvaris N.V.
NASDAQ:PHVS
Intrinsic Alpha fair value
Locked
Current Price
$31.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
BioMarin Pharmaceutical Inc. NASDAQ:BMRN | $11.09B | $57.23 | Undervalued | 39.4 | +17.04% |
Travere Therapeutics, Inc. NASDAQ:TVTX | $4.86B | $50.65 | Overvalued | -235.0 | +39.07% |
Vera Therapeutics, Inc. NASDAQ:VERA | $2.03B | $28.10 | Not rated | -6.8 | -4.02% |
BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX | $1.96B | $7.61 | Undervalued | -4.8 | +4.13% |
Pharming Group N.V. NASDAQ:PHAR | $891.80M | $12.60 | Not rated | 77.0 | -25.11% |
Rallybio Corporation NASDAQ:RLYB | $84.64M | $15.72 | Not rated | -11.6 | +218.03% |
Continue the stock analysis
Jump to another research area for this company.